journal article·2017-07-25

Stimuli-Responsive “Cluster Bomb” for Programmed Tumor Therapy

Qi Lei, Shi-Bo Wang, Jing-Jing Hu, Yi-Xiong Lin, Cheng-Hui Zhu, Lei Rong, Xian-Zheng Zhang

ACS Nano· Volume 11· Issue 7
Publisher page

Abstract

In this paper, mesoporous silica nanoparticle (MSN) loaded with doxorubicin (DOX) and capped with tumor-homing/-penetrating peptide tLyP-1-modified tungsten disulfide quantum dots (WS 2 -HP) was designed and applied as a stimuli-responsive “Cluster Bomb” for high-performance tumor suppression. The peptide tLyP-1 on the surface can both facilitate the homing of DOX@MSN-WS 2 -HP to 4T1 tumor and greatly enhance the penetration of WS 2 -HP in tumor. The benzoic–imine bonds as the linkers between “bomblets” and “dispenser” are stable under normal physical conditions and quite labile at pH 6.8. After arriving at the mild acidic tumor microenvironment, the nanoplatform can rapidly break into two parts: (1) electropositive DOX@MSN-NH 2 for efficient chemotherapy on surface tumor cells and (2) small-sized WS 2 -HP with improved tumor penetrating ability for near-infrared (NIR)-light-triggered photothermal therapy (PTT) among deep-seated tumor cells. Having killed the tumor cells in different depths, DOX@MSN-WS 2 -HP exhibited significant antitumor effect, which will find great potential in clinical trials.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Nanoparticle-Based Drug Delivery · Graphene and Nanomaterials Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Key Laboratory of Biomedical Polymers of Ministry of Education & Department of Chemistry and ‡The Institute for Advanced Studies, Wuhan University, Wuhan 430072, China

Funding

National Natural Science Foundation of China

References (39)

Show source-provided references
1. 10.1158/1078-0432.CCR-04-233210.1158/1078-0432.CCR-04-2332 ↗
2. 10.1038/nrc145610.1038/nrc1456 ↗
3. 10.1016/S0169-409X(00)00131-910.1016/S0169-409X(00)00131-9 ↗
4. Goodman T. T. · Inter. J. Nanomed. · 2007 · 2 · 26510.2217/17435889.2.3.265 ↗
5. 10.1038/nrc189310.1038/nrc1893 ↗
6. 10.1016/j.nantod.2014.04.00810.1016/j.nantod.2014.04.008 ↗
7. 10.1016/j.addr.2016.05.02110.1016/j.addr.2016.05.021 ↗
8. 10.1002/adma.20160190210.1002/adma.201601902 ↗
9. 10.1016/j.biomaterials.2011.11.06410.1016/j.biomaterials.2011.11.064 ↗
10. 10.1021/nn300149c10.1021/nn300149c ↗
11. 10.1021/nn500299p10.1021/nn500299p ↗
12. 10.1021/acsnano.5b0132010.1021/acsnano.5b01320 ↗
13. 10.1021/acsnano.5b0201710.1021/acsnano.5b02017 ↗
14. 10.1073/pnas.152208011310.1073/pnas.1522080113 ↗
15. 10.1021/acsnano.6b0232610.1021/acsnano.6b02326 ↗
16. 10.1002/adfm.20170005610.1002/adfm.201700056 ↗
17. 10.1126/science.118305710.1126/science.1183057 ↗
18. 10.1038/onc.2011.53710.1038/onc.2011.537 ↗
19. 10.1016/j.addr.2016.03.00810.1016/j.addr.2016.03.008 ↗
20. 10.1016/j.biomaterials.2012.10.04810.1016/j.biomaterials.2012.10.048 ↗
21. 10.1016/j.biomaterials.2013.04.02510.1016/j.biomaterials.2013.04.025 ↗
22. 10.1038/ncomms590410.1038/ncomms5904 ↗
23. 10.1016/j.jconrel.2015.06.00910.1016/j.jconrel.2015.06.009 ↗
24. 10.1021/la500595b10.1021/la500595b ↗
25. 10.1016/S0002-9440(10)64083-710.1016/S0002-9440(10)64083-7 ↗
26. 10.1016/j.ccell.2014.10.00610.1016/j.ccell.2014.10.006 ↗
27. 10.1038/ncomms683410.1038/ncomms6834 ↗
28. 10.1093/jnci/djm13510.1093/jnci/djm135 ↗
29. 10.1016/j.addr.2016.05.02210.1016/j.addr.2016.05.022 ↗
30. 10.1109/PROC.1980.1159310.1109/PROC.1980.11593 ↗
31. 10.1016/j.canlet.2008.04.02610.1016/j.canlet.2008.04.026 ↗
32. 10.1002/anie.20131122710.1002/anie.201311227 ↗
33. 10.1021/acsnano.5b0582510.1021/acsnano.5b05825 ↗
34. 10.1002/adma.20130449710.1002/adma.201304497 ↗
35. 10.1021/nn100534q10.1021/nn100534q ↗
36. 10.1002/smll.20160113710.1002/smll.201601137 ↗
37. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
38. 10.1021/acsami.5b0403110.1021/acsami.5b04031 ↗
39. 10.1002/pola.2758410.1002/pola.27584 ↗